Contents

Part I  What Parp is and What it Does

1  History of the Discovery of Poly (ADP-ribose) ........................................... 3
   Takashi Sugimura and Sydney Shall

2  Discovery of the PARP Superfamily and Focus on the Lesser Exhibited But Not Lesser Talented Members ............................................. 15
   Eléa Héberlé, Jean-Christophe Amé, Giuditta Illuzzi, Françoise Dantzer and Valérie Schreiber

3  The Role of PARPs in DNA Strand Break Repair ................................. 47
   Stuart L. Rulten, Françoise Dantzer and Keith W. Caldecott

4  TIPs: Tankyrase Interacting Proteins ....................................................... 79
   Susan Smith

5  PARP and Carcinogenesis .......................................................................... 99
   Junhui Wang, Akira Sato, Hiroaki Fujimori, Yoshio Miki and Mitsuko Masutani

6  Multitasking Roles for Poly(ADP-ribosyl)ation in Aging and Longevity ............................................................................. 125
   Aswin Mangerich and Alexander Bürkle

Part II  NAD Catalysis and the Identification of Inhibitors

7  Overview of PARP Inhibitor Design and Optimization ......................... 183
   Dana Ferraris

8  Structure Based Design of PARP Inhibitors ............................................. 205
   Stacie S. Canan
Part III  Chemo- and Radiosensitisation in Vitro and in Vivo

9 Preclinical Chemosensitization by PARP Inhibitors .................. 225
   David R. Shalinsky, Cherrie K. Donawho, Gerrit Los and Joann P. Palma

10 Classification of PARP Inhibitors Based on PARP Trapping
   and Catalytic Inhibition, and Rationale for Combinations
   with Topoisomerase I Inhibitors and Alkylating Agents.......... 261
   Junko Murai and Yves Pommier

11 Radiosensitisation by Poly(ADP-ribose) Polymerase Inhibition .... 275
   Charles Fouillade, Alexis Fouquin, Mohammed-Tayyib Boudra,
   Vincent Favaudon, Vincent Pennaneach and Janet Hall

12 The Vasoactivity of PARP Inhibitors ..................................... 299
   Cian M. McCrudden and Kaye J. Williams

Part IV  Synthetic Lethality

13 Synthetic Lethality with Homologous Recombination
   Repair Defects ..................................................................... 315
   Helen E. Bryant and Sydney Shall

14 Targeting Tumour Hypoxia with PARP Inhibitors:
   Contextual Synthetic Lethality ............................................. 345
   Katarzyna B. Leszczynska, Nadya Temper, Robert G. Bristow
   and Ester M. Hammond

15 Other Determinants of Sensitivity ....................................... 363
   Naoyuki Okita and Atsushi Shibata

16 Synthetic Sickness with Molecularly Targeted Agents
   Against the EGFR Pathway .................................................. 381
   Jennifer A. Stanley and Eddy S. Yang

17 Disruption of DNA Repair by Cell Cycle and Transcriptional
   CDK Inhibition .................................................................... 413
   Liam Cornell, Neil Johnson and Geoffrey I. Shapiro

18 Resistance to PARP Inhibitors Mediated by Secondary
   BRCA1/2 Mutations .......................................................... 431
   Kiranjit K. Dhillon and Toshiyasu Taniguchi
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>PARP Inhibitor Resistance—What Is Beyond BRCA1 or BRCA2 Restoration?</td>
<td>453</td>
</tr>
<tr>
<td></td>
<td>Guotai Xu, Jos Jonkers and Sven Rottenberg</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Part V  Clinical Status</strong></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Introduction to PARPi Clinical Trials and Future Directions</td>
<td>475</td>
</tr>
<tr>
<td></td>
<td>Ruth Plummer and Yvette Drew</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Clinical Trials Investigating PARP Inhibitors as Single Agents</td>
<td>487</td>
</tr>
<tr>
<td></td>
<td>Sheena Irshad and Andrew Tutt</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Clinical Trials of PARP Inhibitors with Chemotherapy</td>
<td>511</td>
</tr>
<tr>
<td></td>
<td>Ashley K. Clift, Nicholas Coupe and Mark R. Middleton</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Combination of PARP Inhibitors with Clinical Radiotherapy</td>
<td>533</td>
</tr>
<tr>
<td></td>
<td>Ross Carruthers and Anthony J. Chalmers</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Biomarkers for PARP Inhibitors</td>
<td>553</td>
</tr>
<tr>
<td></td>
<td>Charles Dearman, Ricky A. Sharma and Nicola J. Curtin</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Glossary</strong></td>
<td>581</td>
</tr>
<tr>
<td></td>
<td><strong>Index</strong></td>
<td>589</td>
</tr>
</tbody>
</table>
PARP Inhibitors for Cancer Therapy
Curtin, N.; Sharma, R. (Eds.)
2015, XIX, 591 p. 108 illus., 85 illus. in color. With online files/update., Hardcover
ISBN: 978-3-319-14150-3
A product of Humana Press